New Blood-Thinner strategy aims to cut bleeding after heart device implants
NCT ID NCT07616414
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a stepwise blood-thinning approach to the standard method in 424 patients with atrial fibrillation who are at high risk for stroke and need a heart device like a pacemaker. The stepwise plan involves stopping the blood thinner one day before surgery and restarting with a lower dose for a week afterward. The goal is to see if this reduces pocket hematoma (bleeding under the skin) within 30 days after surgery, while still preventing blood clots.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
edoxaban or rivaroxaban (blood thinners)
What this could lead to
If successful, this could offer a safer way to manage blood thinners around heart device surgery, reducing bleeding complications while still preventing strokes.
What could go wrong
This is an early-stage trial with only 424 participants, so results may not apply to all patients. The stepwise approach might not lower bleeding risk as expected or could increase stroke risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIOPERATIVE BLEEDING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fuwai Hospital
Beijing, Beijing Municipality, 100037, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact